Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

21.03
+0.17000.81%
Volume:2.66M
Turnover:55.56M
Market Cap:2.22B
PE:-15.98
High:21.16
Open:20.56
Low:20.18
Close:20.86
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:0.78
T/O Rate:2.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.45
PE(LYR):-2.95

Loading ...

Earning Preview: Sarepta Therapeutics this quarter’s revenue is expected to decrease by 30.61%, and institutional views are neutral

Earnings Agent
·
Apr 30

Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Sarepta Therapeutics (SRPT)

TIPRANKS
·
Apr 23

Sarepta to report first-quarter results, host conference call

Reuters
·
Apr 22

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

THOMSON REUTERS
·
Apr 22

Analysts Are Bullish on Top Healthcare Stocks: Evommune, Inc. (EVMN), Sarepta Therapeutics (SRPT)

TIPRANKS
·
Apr 17

Will Roche’s New Global Elevidys Phase 3 Trial Shift Sarepta Therapeutics' (SRPT) Gene Therapy Narrative?

Simply Wall St.
·
Apr 17

Sarepta Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 17

Analysts Conflicted on These Healthcare Names: Rhythm Pharmaceuticals (RYTM) and Sarepta Therapeutics (SRPT)

TIPRANKS
·
Apr 17

Roche decision could hurt Sarepta in U.S., says H.C. Wainwright

TIPRANKS
·
Apr 17

A Look At Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Swings

Simply Wall St.
·
Apr 10

RBC Adjusts Price Target on Sarepta Therapeutics to $19 From $18, Maintains Sector Perform Rating

MT Newswires Live
·
Apr 07

Is Sarepta Therapeutics (SRPT) Starting To Look Interesting Again After Recent Share Price Rebound

Simply Wall St.
·
Apr 07

Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)

TIPRANKS
·
Apr 01

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 01

Sarepta Therapeutics Is Maintained at Sell by Citigroup

Dow Jones
·
Mar 26

Deutsche ups Sarepta target, says 35% stock rally overdone

TIPRANKS
·
Mar 26

Sarepta price target raised to $35 from $29 at Wedbush

TIPRANKS
·
Mar 26

Wedbush Raises Price Target on Sarepta Therapeutics to $35 From $29, Keeps Outperform Rating

MT Newswires Live
·
Mar 26

Sarepta Therapeutics, Inc. : Deutsche Bank Raises Target Price to $14 From $12

THOMSON REUTERS
·
Mar 26

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT)

TIPRANKS
·
Mar 26